NCT06497049已完成1 期
An Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221, Solution for Subcutaneous Administration 1.34 mg/ml (GEROPHARM) and Ozempic®, Solution for Subcutaneous Administration 1.34 mg/ml in Healthy Volunteers
Geropharm1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2023年6月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
Study of comparative pharmacokinetics and biosimilarity of drugs containing semaglutide - GP40221 and Ozempic® in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Signed informed consent to participate in the study.
- •Males with a verified diagnosis "healthy" according to the data of standard clinical, laboratory and instrumental examination methods.
- •Age 18-45 years old inclusive.
- •Body mass index 18.5 - 29.9 kg/m
- •Agree to use an adequate method of contraception (double barrier method) during the entire period of participation in the study and for 3 weeks after its completion.
- •Consent to all restrictions imposed during the study.
- •Citizenship of the Russian Federation.
排除标准
- •Burdened allergic history, drug intolerance.
- •Hypersensitivity to heparin, semaglutide and any of the excipients of the study drug.
- •Any acute and chronic diseases, incl. but not limited to:
- •diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract (including diseases of the colon), liver, kidneys, blood;
- •positive test results for hepatitis C (antibodies) or hepatitis B (surface antigen), HIV (antibodies to HIV-1/2), syphilis (antibodies to Treponema pallidum).
- •Deviations from normal values of heart rate (60-80), SBP (100-130 mm Hg), DBP (60-85 mm Hg), NPV (16-20), body temperature (35.7 - 37.0 °C).
- •ECG Deviations, according to a specialist, during screening.
- •laboratory tests results deviations from the normal values.
- •Hard-to-reach veins of the upper extremities, vein thrombosis, thrombophlebitis in a family history of close relatives, "compromised" veins due to frequent previous venipunctures.
- •Surgical interventions on the gastrointestinal tract (with the exception of appendectomy) in history.
- •Acute infectious diseases less than 4 weeks prior to screening.
- •History of medullary thyroid cancer and/or multiple endocrine neoplasia type 2, including family history.
- •History of chronic or acute pancreatitis.
- •Regular use of any prescription and over-the-counter medications (in particular drugs that reduce heart rate), dietary supplements, vitamins less than 2 weeks before the start of screening, taking St. John's wort (Hypericum perforatum) less than 30 days before the start screening.
- •Use of semaglutide or other analogues of human glucagon-like peptide-1 (GLP-1) within 6 months before screening.
- •Use of depot injections or implants of any medications 3 months before the start of screening.
- •Significant blood loss (more than 450 ml of blood or plasma) within 3 months prior to screening, due to, including, but not limited to, blood donation, blood loss during advanced surgery or trauma.
- •Drinking alcohol in quantities exceeding 10 units per week (on average) (1 unit of alcohol is equivalent to 500 ml of beer, 200 ml of dry wine or 50 ml of strong alcoholic drinks) or anamnestic information about alcoholism, drug addiction, abuse of strong drugs.
- •Positive test results for alcohol, drug use and the use of strong drugs.
- •Nicotine addiction (regular tobacco use, including smoking of all types of electronic cigarettes, hookahs, snuff, etc. less than 6 months prior to screening).
- •Participation in a clinical trial of any drugs (including experimental drugs) or experimental medical devices for 3 months or 5 half-lives prior to Screening, whichever is longer.
- •Any diet (eg vegetarian, fasting, etc.) or lifestyle (including night work and extreme physical activity such as heavy lifting) that may interfere with the study.
- •Taking drugs that have a pronounced effect on hemodynamics, liver function, etc. (barbiturates, omeprazole, cimetidine, etc.) less than 30 days before screening.
- •Consumption of citrus fruits (including grapefruit and grapefruit juice), cranberries (juice, fruit drink, etc.), starfruit or pomelo 14 days before the start of screening.
- •Incomplete recovery from surgery or surgery scheduled while the volunteer was participating in the study.
- •Other diseases/conditions that, in the opinion of the researcher, may affect the pharmacokinetics of the active substance of the drugs or increase the risk to the health of the volunteer.
- •Tattoos or piercings less than 30 days before screening.
- •Volunteers who are obviously or likely, in the opinion of the investigator, unable to understand and evaluate the information on this study as part of the informed consent process, in particular regarding expected risks and possible discomfort.
研究组 & 干预措施
GP40221
Experimental
GP40221 is administered subcutaneously into the subcutaneous fat of the anterior abdominal wall at a dose of 0.5 mg using a pen injector.
干预措施: GP40221 (Drug)
ozempic
Active Comparator
Ozempic® is administered subcutaneously into the subcutaneous fat of the anterior abdominal wall at a dose of 0.5 mg using a pen injector
干预措施: ozempic (Drug)
结局指标
主要结局
Cmax
时间窗: -60, -30, 0 minutes and 2, 4, 8, 10, 12, 16, 24, 36, 48, 60, 72, 96, 144, 192, 240, 288 hours after injection
Maximum concentration of the active substance in the blood plasma of volunteers during the observation period
AUC 0-t
时间窗: -60, -30, 0 minutes and 2, 4, 8, 10, 12, 16, 24, 36, 48, 60, 72, 96, 144, 192, 240, 288 hours after injection
Total area under the "concentration of an active substance - time" curve in the time interval from 0 (the moment of drug administration) to the collection of the last blood sample with a determined concentration of the active substance at time point t
次要结局
- tmax(-60, -30, 0 minutes and 2, 4, 8, 10, 12, 16, 24, 36, 48, 60, 72, 96, 144, 192, 240, 288 hours after injection)
- t1/2(-60, -30, 0 minutes) and 2, 4, 8, 10, 12, 16, 24, 36, 48, 60, 72, 96, 144, 192, 240, 288 hours after injection)
- AUC0-∞(-60, -30, 0 minutes) and 2, 4, 8, 10, 12, 16, 24, 36, 48, 60, 72, 96, 144, 192, 240, 288 hours after injection)
- λz(-60, -30, 0 minutes) and 2, 4, 8, 10, 12, 16, 24, 36, 48, 60, 72, 96, 144, 192, 240, 288 hours after injection)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 DiabetesDiabetes Mellitus, Type 2NCT05478252Novo Nordisk A/S388
已完成
1 期
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityObesityNCT06716307Novo Nordisk A/S18
尚未招募
3 期
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 DiabetesType 2 Diabetes MellitusNCT06339086Chengdu Brilliant Pharmaceutical Co., Ltd.478
已完成
1 期
A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IIIHealthy ParticipantsNCT06097390Novo Nordisk A/S121
已完成
1 期
Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy MenDiabetes Mellitus, Type 2NCT03638778Novo Nordisk A/S105